There was a good discussion re reimbursement at today's #Esmo26 press conf. If you're a health authority that doesn't reimburse Lumakras, do you care that divarasib has beaten Luma

Jacob Plieth· @JacobPlieth · X·2026-10-25 23:42· 17 hours agoScore70

Body

There was a good discussion re reimbursement at today's #Esmo26 press conf. If you're a health authority that doesn't reimburse Lumakras, do you care that divarasib has beaten Lumakras (whose benefit you don't recognise)? #Kras

499 views · 1 like · 0 reposts · 1 reply

引用@

Interesting tidbit from Krascendo-1 divarasib trial. In the control group, only 9% of pts got Krazati, "owing to limited drug availability worldwide" $RHHBY $AMGN $BMY #ESMO26

在 X 查看被引用的帖子

Replies in this thread

Jacob Plieth@JacobPlieth
And here's the KRAS inhibitor reimbursement picture, via Benjamin Besse #Esmo26

Source: Jacob Plieth · x.com